Serina dosed its first patient in February 2026 and is conducting a randomized, double-blind, placebo-controlled Phase 1b trial of SER-252 in advanced Parkinson’s disease. Cohort 1 enrollment and dosing are targeted for completion by the end of Q3 2026, with single-ascending-dose (SAD) data expected in H1 2027.

In March and April 2026, Serina closed a private placement issuing common stock, redeemable warrants, and pre-funded warrants, raising $21.2 million gross. The financing amended a convertible promissory note, eliminated Series A preferred obligations, and triggered conversion into common stock, with an additional $5.2 million received in April.

For the quarter ended March 31, 2026, operating expenses rose to $6.3 million from $5.9 million a year earlier, driven by $3.2 million in R&D and $3.1 million in G&A. Other expense was $0.6 million versus $1.0 million income in 2025, leading to a net loss of $6.9 million ($0.58 per share) compared to $4.8 million ($0.49) previously.

Serina’s proprietary POZ Platform™ leverages poly(2-oxazoline) to optimize drug pharmacokinetics and tolerability across modalities. The company is building out its pipeline, exploring out-licensing and co-development opportunities, and collaborating with Pfizer on lipid nanoparticle delivery applications.